Announcement PDF RNS Number : 0546W N4 Pharma PLC 07 December 2023 TR-1: Standard form for notification of major holdings 1a. Identity of the issuer or the underlying issuer of N4 Pharma PLC existing shares to which voting rights are attachedii: 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer 2. Reason for the notification (please mark the appropriate box or boxes with an "X") An acquisition or disposal of voting rights X An acquisition or disposal of financial instruments An event changing the breakdown of voting rights Other (please specify)iii: 3. Details of person subject to the notification obligationiv Name DAVID FARRIER City and country of registered office (if applicable) UK 4. Full name of shareholder(s) (if different from 3.)v Name City and country of registered office (if applicable) 5. Date on which the threshold was crossed or reachedvi: 6. Date on which issuer notified (DD/MM/YYYY): 6 DECEMBER 2023 7 DECEMBER 2023 7. Total positions of person(s) subject to the notification obligation % of voting rights attached to shares (total of 8. A) Resulting situation on the date on which threshold was crossed or reached Position of previous notification (if applicable) % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) 5.96% 5.96% 4.67% 4.67% Total number of voting rights of issuervii 268,780,349 8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii A: Voting rights attached to shares Class/type of Number of voting rightsix shares Indirect Direct ISIN code (if (Art 10 of Directive (Art 9 of Directive possible) 2004/109/EC) (DTR5.2.1) 2004/109/EC) (DTR5.1) GB00BYW8QM32 16,040,954 SUBTOTAL 8. A 0 % of voting rights Direct Indirect (Art 9 of Directive 2004/109/EC) (DTR5.1) (Art 10 of Directive 2004/109/EC) (DTR5.2.1) 5.96 0 16,040,954 5.96 B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) Type of financial instrument Expiration datex Exercise/ Conversion Periodxi Number of voting rights that may be acquired if the instrument is exercised/converted. % of voting rights SUBTOTAL 8. B 1 B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) Exercise/ Physical or Type of Expiration Number of Conversion cash financial % of voting rights voting rights datex instrument Period xi settlementxii SUBTOTAL 8.B.2 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii X Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary) Namexv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold 10. In case of proxy voting, please identify: Name of the proxy holder N/A The number and % of voting rights held N/A The date until which the voting rights will be held N/A 11. Additional informationxvi N/A Place of completion UK Date of completion 6 DECEMBER 2023 This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END HOLFLFFLFELDIIV